Serratosa Inés, Déniz Carlos, Moreno Camilo, Macia Iván, Rivas Francisco, Muñoz Anna, Paradela Marina, Nadal Ernest, Mosteiro Miguel, Padrones Susana, García Marta, Rodríguez-Martos Tania, Marcè Judith, Ojanguren Amaia
Department of Thoracic Surgery, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, 08907 Barcelona, Spain.
Cancers (Basel). 2024 Nov 25;16(23):3938. doi: 10.3390/cancers16233938.
Neoadjuvant therapy, particularly the combination of chemotherapy and immunotherapy, has become standard in treating locally advanced non-small cell lung cancer (NSCLC). While this approach improves pathologic responses, its effect on postoperative outcomes following robotic-assisted thoracic surgery (RATS) is not fully characterized. This study aimed to evaluate the impact of neoadjuvant therapy on postoperative outcomes in patients undergoing RATS for NSCLC, focusing on operative time, conversion rates to open surgery, and postoperative complications. A retrospective cohort analysis was performed on patients who underwent RATS for NSCLC between February 2019 and August 2024. Propensity score matching was utilized to balance preoperative characteristics between the groups. The primary outcomes compared were operative time, conversion rates to open surgery, and postoperative complications, with statistical significance defined as < 0.05. A total of 253 patients were included in the analysis, of whom 23 received neoadjuvant therapy (either chemotherapy or chemoimmunotherapy) and 230 did not. The neoadjuvant group had significantly longer operative times (250 min vs. 221 min, = 0.001) but there were no significant differences in conversion rates to open surgery (8.7% vs. 3.9%, = 0.5). However, the neoadjuvant group showed a higher incidence of prolonged air leaks (>5 days) (39.13% vs. 35.21%, < 0.001). Other parameters, such as hospital stay and chest drainage duration, showed no statistically significant differences between the groups ( = 0.860 and = 0.760, respectively). These findings support the feasibility of robotic-assisted thoracic surgery following neoadjuvant therapy in NSCLC, suggesting that this approach may be safely integrated into clinical practice for selected patients. Further studies are needed to define patient selection criteria and optimize postoperative management, potentially guiding personalized treatment strategies in complex cases.
新辅助治疗,尤其是化疗与免疫治疗的联合应用,已成为局部晚期非小细胞肺癌(NSCLC)治疗的标准方法。虽然这种方法可改善病理反应,但其对机器人辅助胸外科手术(RATS)术后结局的影响尚未完全明确。本研究旨在评估新辅助治疗对接受RATS治疗的NSCLC患者术后结局的影响,重点关注手术时间、转为开胸手术的比例以及术后并发症。对2019年2月至2024年8月期间接受RATS治疗的NSCLC患者进行了回顾性队列分析。采用倾向评分匹配法平衡两组患者的术前特征。比较的主要结局为手术时间、转为开胸手术的比例和术后并发症,统计学显著性定义为<0.05。共有253例患者纳入分析,其中23例接受了新辅助治疗(化疗或化疗联合免疫治疗),230例未接受新辅助治疗。新辅助治疗组的手术时间显著更长(250分钟对221分钟,P = 0.001),但转为开胸手术的比例无显著差异(8.7%对3.9%,P = 0.5)。然而,新辅助治疗组出现长时间漏气(>5天)的发生率更高(39.13%对35.21%,P<0.001)。其他参数,如住院时间和胸腔引流持续时间,两组之间无统计学显著差异(分别为P = 0.860和P = 0.760)。这些结果支持了新辅助治疗后在NSCLC患者中进行机器人辅助胸外科手术的可行性,表明这种方法可安全地纳入特定患者的临床实践。需要进一步研究以确定患者选择标准并优化术后管理,可能为复杂病例指导个性化治疗策略。